June 24, 2022
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Apr 30, 2018 • PDFFDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell CarcinomaApr 18, 2018 • PDFSanofi Jordan launches its Next Generation Basal Insulin Glargine U-300Apr 3, 2018 • PDFEMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
Mar 28, 2018 • PDFSanofi Completes Acquisition of Bioverativ Inc.Mar 10, 2018 • PDFSanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet needMar 10, 2018 • PDFPraluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rateAug 3, 2018 • PDFSanofi Completes Acquisition of Bioverativ Inc.
Get in touch
Sanofi Aventis Groupe, Mecca Street, Al Hijaz Towers for Investment, 8th Floor
PO BOX 922464, Amman 11192 Jordan
(962) 6 55 63 6 60 Contactus.email@example.com
You are about to leave Sanofi.jo
You are about to visit another Sanofi website that is not governed by Jordan regulatory.